Booster dose of Pfizer/BioNTech coronavirus vaccine shows 95.6% efficacy in Phase 3 trial, companies say

Jackson Progress Argus

Oct 21, 2021

A booster dose of the Pfizer/BioNTech coronavirus vaccine was found to have a high efficacy -- 95.6% -- against Covid-19 in a Phase 3 trial, the companies announced on Thursday. Th…